tbuckley/cabot-search huggingface dataset:
Medical News
Journal: JAMA (1935)

<h3>ALABAMA</h3><h3>Personal.—</h3> Dr. William D. Gaines, Lafayette, has been appointed physician to the state prison at Atmore.—Dr. Cornelius S. Hagerty, resident pathologist at Presbyterian Hospital, Chicago, has received an appointment as assistant professor of bacteriology and pathology at the University of Alabama School of Medicine. <h3>Bill Introduced.—</h3> H. 300 proposes to prohibit the sale or distribution of barbital, sulphonethylmethane (trional), sulphonmethane (sulphonal), diethylsulphon diethylmethane (tetronal), paraldehyde and chloral or chloral hydrate and any derivatives, compounds or mixtures of any of the foregoing drugs possessing hypnotic properties or effects, except on the written prescription of a licensed physician. <h3>Society News.—</h3> Dr. James S. McLester, Birmingham, President-Elect of the American Medical Association, among others, addressed the Tuscaloosa County Medical Society, recently, on "Present Status of Kidney Function Tests." —Speakers before the Northeastern Division of the Medical Association of Alabama in Talladega, recently, in joint session with the Talladega County Medical Society, were
Abstract 4039: Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy
Authors: Rachel Krupa, Robin Richardson, Priscilla Ontiveros, Joseph Schonhoft, Jiyun Byun, David Lu, Sean Nisperos, Yipeng Wang, Mark Landers, Ryan Dittamore
Journal: Cancer Research (2019)

Abstract Purpose: Activated immune cell subpopulations and circulating tumor cells in patients receiving checkpoint inhibitor therapy were characterized with the aim of developing more sensitive diagnostic tools for prediction of immunotherapy response or resistance. Methods: Blood samples from bladder, kidney, and prostate cancer patients undergoing checkpoint inhibitor therapy were collected at baseline and on-therapy at convenience and sent to Epic Sciences for processing. Red blood cells were lysed and nucleated cells were plated onto glass slides and stained with CTC (pan-CK, CD45, PD-L1 and DAPI) and immune panels (CD4, CD8, Ki-67, and DAPI). 2-3 million cells per patient were imaged using high throughput digital pathology pipelines and changes in immune cell sub-populations and changes in circulating tumor cell (CTC) burden with PD1/PD-L1 immunotherapy were assessed. Results: A method to profile activated (CD8+Ki-67+ and CD4+Ki-67+) leukocyte subpopulations and PD-L1+ CTCs in a single blood sample was developed and feasibility was demonstrated in cell lines, healthy donor (HD), and patient blood. CTCs were detected in 73% (24/33) of patients tested. Of the 33 baseline samples tested, 12% (4/33) had PD-L1+ CTCs detected. No PD-L1+ CTCs were detected in on-therapy samples. Of 14 patients with matched samples, 57% (8/14) patients had an increase in activated CD4+ leukocytes and 36% (5/14) patients had an increase in activated CD8+ leukocytes in on-therapy samples compared to baseline. A decrease in activated CD4+ leukocytes was observed in 21% (3/14) patients and a decrease in activated CD8+ leukocytes was also observed in 7% (1/14) patients with therapy. Conclusions: We developed a liquid biopsy-based platform that can simultaneously measure immune related biomarkers in CTCs and leukocytes at single cell resolution from ~1 mL of blood. The platform has extreme sensitivity over conventional methodologies and immune cell populations existing in less than 1% of the total are readily quantified. Efforts to identify morphological sub-populations within each canonical leukocyte category and comparison of leukocyte and CTC biomarker panels to patient outcomes are ongoing. Citation Format: Rachel Krupa, Robin Richardson, Priscilla Ontiveros, Joseph Schonhoft, Jiyun Byun, David Lu, Sean Nisperos, Yipeng Wang, Mark Landers, Ryan Dittamore. Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4039.
A Popular Encyclopedia of Health.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inappropriate expression of blood group antigens in hepatic allografts
Authors: S Bloom
Journal: Hepatology (1994)

We examined the expression of blood group antigens of the ABO, Lewis and Kell antigen systems using monoclonal antibodies and immunohistochemical study on 42 liver allograft specimens from 33 patients who underwent liver transplantation between 1986 and 1991 to learn whether altered blood group antigen expression might have a bearing on the immunopathogenesis of transplant rejection. Specimens were obtained at intervals of 0 days to 3 yr after transplant; they yielded the following histological diagnoses; time zero (n = 4), acute rejection (n = 4), pure cholestasis (n = 4), biliary obstruction (n = 4), early chronic rejection (n = 4), end-stage chronic rejection (n = 15) and miscellaneous late posttransplant biopsies (n = 7). Aberrant expression of blood group antigens was observed in 5 of 15 patients with chronic rejection. Two transplants into the same group O patient showed aberrant expression of AB antigens on hepatocytes, with a canalicular pattern, in group O–transplanted livers. In all three cases in which a group O liver was transplanted into a group A recipient and histological signs of chronic rejection were present, antibody staining showed acquisition of recipient blood phenotype by the donor liver bile ducts, endothelium or both. Aberrant expression of ABO antigens was seen only in chronic rejection. In seven cases we noted canalicular staining of periportal hepatocytes with the Lewis antibodies, normally confined to ducts and ductules. This was associated with severe cholestasis in six of the seven cases and may have represented early ductular metaplasia. These changes in carbohydrate cell surface phenotype may play a role in regulation of hepatic allograft susceptibility to immune-mediated damage. (HEPATOLOGY 1994;19:876–881.)
The Population Impact of Severe Mental Illness on Violent Crime
Authors: Seena Fazel
Journal: American Journal of Psychiatry (2006)

Objective: This study aimed to determine the population impact of patients with severe mental illness on violent crime. Method: Sweden possesses high-quality national registers for all hospital admissions and criminal convictions. All individuals discharged from the hospital with ICD diagnoses of schizophrenia and other psychoses (N=98,082) were linked to the crime register to determine the population-attributable risk of patients with severe mental illness to violent crime. The attributable risk was calculated by gender, three age bands (15–24, 25–39, and 40 years and over), and offense type. Results: Over a 13-year period, there were 45 violent crimes committed per 1,000 inhabitants. Of these, 2.4 were attributable to patients with severe mental illness. This corresponds to a population-attributable risk fraction of 5.2%. This attributable risk fraction was higher in women than men across all age bands. In women ages 25–39, it was 14.0%, and in women over 40, it was 19.0%. The attributable risk fractions were lowest in those ages 15–24 (2.3% for male patients and 2.9% for female patients). Conclusions: The population impact of patients with severe mental illness on violent crime, estimated by calculating the population-attributable risk, varies by gender and age. Overall, the population-attributable risk fraction of patients was 5%, suggesting that patients with severe mental illness commit one in 20 violent crimes.
A Population-Based Study of Neuroblastoma Incidence, Survival, and Mortality in North America
Authors: Mark L. Bernstein, Jean Marie Leclerc, Greta Bunin, Linda Brisson, Les Robison, Jonathan Shuster, Tim Byrne, Diana Gregory, Gerry Hill, Geoff Dougherty, Charles Scriver, Bernard Lemieux, Mendel Tuchman, William G. Woods
Journal: Journal of Clinical Oncology (1992)

In the February 1992 report entitled "A Population-Based Study of Neuroblastoma Incidence, Survival, and Mortality in North America" by Bernstein et al (J Clin Oncol 10:323–329, 1992), the parenthetical ratios that immediately follow the incidence figures per million population were incorrect. The ratios should have reflected cumulative incidence figures based on the geographic- and age-specific rates. Consequently, on page 324, in the Results section, paragraph 2, beginning with the third sentence, the text should read as follows: "The annual incidence rate of neuroblastoma was calculated to be 11.32/10 6 for children under 15 years of age in Quebec (cumulatively, approximately 1/5,889) and 27.47/10 6 under 5 years of age (approximately 1/7,281). In the GDV, the rates were 10.58/10 6 for children under 15 years of age (1/6,301) and 28.03/10 6 for children under 5 years of age (1/7,135) ... the combined incidence data are 27.75/10 6 for children under 5 years of age (1/7,207) and 10.95/10 6 for under 15 years of age (1/6,088). Similarly, in the Discussion section, paragraph 1, the text should read: "Combining ... the annual incidence of neuroblastoma ... is 10.95/10 6 for children aged 0 to 14 years (approximately 1/6,088) and, ... 27.75/10 6 for children aged 0 to 4 years. This is approximately 1/7,207 children under the age of 5 years."
Antibody Response to Tetanus Toxoid 15 Years After Initial Immunization
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Genie in the Bottle
Authors: Michael Bernstein
Journal: Annals of Internal Medicine (1998)

Letters15 December 1998The Genie in the BottleMichael Bernstein, MDMichael Bernstein, MDMurray Hill, NJ 07974Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-12-199812150-00039 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:To follow up on my recent piece in Annals [1], I did receive confirmation at the end of the double-blind growth hormone study that I had been receiving 1.1 mg of growth hormone for the entire 12-month period. At the conclusion of the study, I continued somatropin treatment, in addition to my other replacement therapy my own endocrinologist prescribed. I continue to receive this regimen, and none of the original crippling problems have returned.References1. Bernstein M. The genie in the bottle. Ann Intern Med. 1998; 128:595-6. Google Scholar Author, Article, and Disclosure InformationAuthors: Michael Bernstein, MDAffiliations: Murray Hill, NJ 07974 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 December 1998Volume 129, Issue 12Page: 1082KeywordsGrowth hormone ePublished: 15 August 2000 Issue Published: 15 December 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Chronic Osteomyelitis
Authors: William F. West
Journal: JAMA (1970)

Certain factors affect the success or failure of surgical treatment of chronic osteomyelitis of the major bones of the extremities and the pelvic and shoulder girdles. This study included 186 patients with 217 surgical procedures. Follow-up periods varied from 4 to 14 years. Two important factors affected success: resistance of Staphylococcus aureus to penicillin G potassium or penicillin G sodium and duration of infection. Either of these factors alone did not mitigate against a successful result but when both were present in an etiologic group, such as chronic osteomyelitis in a fracture with union, failure was more frequent than success. Other factors associated with failure, such as scarred soft tissues and bony sclerosis, are a reflection of prolonged disease.
Clonazepam: effective treatment for restless legs syndrome in uraemia
Authors: W. Braude, T. Barnes
Journal: BMJ (1982)

thiazides, chlorthalidone, indapamide, as shown by Drs Fonseca and Phear, and now xipamide.We suggest caution in the use of diuretics in the elderly, since not all patients developing the syndrome have such a favour- able outcome-and since other adverse effects, particularly hypokalaemia, postural hypotension, and glucose intolerance of less sinister proportions, may go unrecognised.
Large study of teratogenic potential of anticonvulsants
Authors: B. J. Montgomery
Journal: JAMA (1979)

Because of clinical observations regarding birth defects in children born to mothers who receive anticonvulsant therapy during pregnancy, several antiseizure agents have been implicated as human teratogens. This in turn has raised questions about the possible teratogenicity of other antiseizure agents. At the National Institute of Environmental Health Sciences (Research Triangle, Raleigh, NC), some members of the Laboratory of Environmental Toxicology have been evaluating the embryopathic potential of three classes of anticonvulsants: oxazolidones, hydantoins, and succinimides. To date, according to John Kao, PhD, Gary Shill, PhD, and Sergio Fabro, MD, PhD, 20 compounds have been tested in 4,000 different mice of one strain. Embryopathic effects have been detected for all three classes of agents. In the first of a series of reports expected on this research project, the investigators said that oxazolidone, hydantoin, and succinimide anticonvulsants were given to the mice between the eighth and tenth days of pregnancy. Estimated
Discoverer of the cause of milk sickness (Anna Pierce Hobbs Bixby)
Authors: W. D. Snively
Journal: JAMA (1966)

The season was fall, the year about 1834. The savagery of the southern Illinois backwoods seemed reflected in the wildly beautiful autumnal foliage. Anna Pierce Hobbs, pioneer doctor in the rugged hills of southeastern Illinois, strode into the dense forest covering Hobbs' Ridge. It was a lovely day to carry on her determined hunt for the unknown killer herb that, she was certain, had been decimating both the human and livestock populations of the pioneer settlement of Rock Creek. Anna had no inkling that, on this day, she would meet the Shawnee medicine woman, "Aunt Shawnee," who would reveal to her the guilty plant. She little thought that she was about to take the last in a series of logical steps that were to lead, inevitably, to her discovery of the cause of milk sickness. Anna's work, reaching its culmination on this day, should have wiped out the vicious scourge
EARLY RISING AFTER SURGICAL OPERATION
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fundamentals of Dietetics. A Text-Book for Nurses and Dietitians.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the NIH: Hormonal requirements of endometriosis yield clues to treatment
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ghrelin Induces Abdominal Obesity via GHS-R-Dependent Lipid Retention
Authors: Jeffrey S. Davies, Pia Kotokorpi, Sinan R. Eccles, Sarah K. Barnes, Paweł F. Tokarczuk, Sophie K. Allen, Hilary S. Whitworth, Irina A. Guschina, Bronwen A. J. Evans, Agneta Mode, Jeffrey M. Zigman, Timothy Wells
Journal: Endocrine Reviews (2009)

Circulating ghrelin elevates abdominal adiposity by a mechanism independent of its central orexigenic activity. In this study we tested that hypothesis that peripheral ghrelin induces a depot-specific increase in white adipose tissue (WAT) mass in vivo by growth hormone secretagogue receptor (GHS-R1a)-mediated lipolysis. Chronic intravenous infusion of acylated ghrelin increased retroperitoneal and inguinal WAT volume in rats without elevating superficial subcutaneous fat, food intake or circulating lipids and glucose. Increased retroperitoneal WAT mass resulted from adipocyte enlargement probably due to reduced lipid export [ATP-binding cassette transporter (ABCG1) mRNA expression and circulating free fatty acids (FFAs) were halved by ghrelin infusion]. In contrast, ghrelin treatment did not upregulate biomarkers of adipogenesis [peroxisome proliferator-activated receptor (PPAR)γ2 or CCAAT/enhancer binding protein (C/EBP)α] or substrate uptake (glucose transporter, GLUT4, lipoprotein lipase or CD36) and although ghrelin elevated sterol regulatory element binding protein (SREBP)1c expression, WAT-specific mediators of lipogenesis [liver X receptor (LXR)α and fatty acid synthase] were unchanged. Adiposity was unaffected by infusion of unacylated ghrelin, and the effects of acylated ghrelin were abolished by transcriptional blockade of GHS-R1a, but GHS-R1a mRNA expression was similar in responsive and unresponsive WAT. Microarray analysis suggested that depot-specific sensitivity to ghrelin may arise from differential fine-tuning of signal transduction and/or lipid handling mechanisms. Acylated ghrelin also induced hepatic steatosis, increasing lipid droplet number and triacylglycerol content by a GHS-R1a-dependent mechanism. Our data imply that during periods of energy insufficiency exposure to acylated ghrelin may limit energy utilization in specific WAT depots by GHS-R1a-dependent lipid retention.